Covid-19 News and Discussions


COVID-19 shatters decades of global health progress, slashing life expectancy​

NewsGuard 100/100 Score
Tarun Sai Lomte
By Tarun Sai LomteApr 7 2024Reviewed by Susha Cheriyedath, M.Sc.
A recent study published in The Lancet presented the global burden of 288 mortality causes and life expectancy decomposition.
The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has been analyzing causes of human death for over three decades, which has been used to guide policies, monitor/assess health interventions, and reduce risk factors. Assessing cause-specific mortality trends helps inform health policies, which must evolve to account for changes in the global health landscape.
Mortality patterns evolve continually as some areas succeed in reduction efforts while other causes linger in specific locations. Further, there have been improvements in several causes of death in the past three decades, some of which have substantially narrowed geographically and are concentrated in smaller areas.
Study: Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Image Credit: tomertu / ShutterstockStudy: Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Image Credit: tomertu / Shutterstock

About the study​

In the present study, researchers presented mortality concentrations and life expectancy decomposition. GBD 2021 provided a comprehensive set of the fatal disease burden for 288 causes by sex and age in 204 countries and territories between 1990 and 2021, an update from previous estimates for 1990–2019. The team calculated years of life lost (YLLs) as the product of death count for each cause, age, sex, year, and location, as well as standard life expectancy at each age.
Cause-specific mortality rates were computed using the causes of death ensemble model for most causes, and alternative strategies were applied to model causes with unusual epidemiology or insufficient data. Diseases and injuries were classified into four levels, with both non-fatal and fatal causes. Level 1 causes included three broad aggregate categories: 1) non-communicable diseases (NCDs), 2) communicable, maternal, neonatal, and nutritional (CMNN) diseases, and 3) injuries.
Level 2 disaggregated these categories into 22 clusters, which were further disaggregated into levels 3 and 4 causes. Life expectancy was decomposed by cause of death, year, and location to explore cause-specific effects on life expectancy between 1990 and 2021. Concentrated causes were estimated using the coefficient of variation and mortality concentration (the fraction of the population affected by 90% of deaths).
Global choropleth maps of COVID-19 (A) and OPRM (B) for 2021 that show sub-national detail where available.

Global choropleth maps of COVID-19 (A) and OPRM (B) for 2021 that show sub-national detail where available. OPRM=other pandemic-related mortality.

Findings​

During 1990–2019, the annual rate of change in all-cause global mortality ranged between -0.9% and 2.4%. The corresponding rate in age-standardized deaths ranged between -3.3 and 0.4%. Nevertheless, deaths increased by 10.8% worldwide in 2020 compared to 2019. This persisted in 2021, with a 7.5% increase relative to 2020. Likewise, the age-standardized mortality rate showed a similar pattern, increasing 8.1% in 2020 and 5.2% in 2021.
Each row represents the change in life expectancy from 1990 to 2021 for a given GBD region. A bar to the right of 0 represents an increase in life expectancy due to changes in the given cause, and a bar to the left of 0 represents a decrease in life expectancy for a given cause. For readability, labels indicating a change in life expectancy of less than 0·3 years are not shown.

Related Stories​

Each row represents the change in life expectancy from 1990 to 2021 for a given GBD region. A bar to the right of 0 represents an increase in life expectancy due to changes in the given cause, and a bar to the left of 0 represents a decrease in life expectancy for a given cause. For readability, labels indicating a change in life expectancy of less than 0·3 years are not shown. CKD=chronic kidney disease. COPD=chronic obstructive pulmonary disease. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. LRI=lower respiratory infection. NCD=non-communicable disease. OPRM=other pandemic-related mortality. *Does not include war and terrorism. †Does not include natural disasters.
In 2020-21, coronavirus disease 2019 (COVID-19) deaths and other pandemic-related mortality (OPRM) altered mortality patterns for the leading causes of age-standardized death. At level 3, the rankings of the four mortality causes (1. ischemic heart disease, 2. stroke, 3. chronic obstructive pulmonary disease, and 4. lower respiratory infections) with the highest age-standardized rates in 2019 were the same as in 1990.
However, in 2021, stroke became the third leading cause of age-standardized mortality, as COVID-19 eclipsed it as the second leading cause. Besides, OPRM was the fifth leading cause, whereas lower respiratory infections became the seventh leading cause. Although the impact of COVID-19 on age-standardized mortality was similar to that of common obstructive pulmonary disease in 2020, it increased by 60.2% in 2021.
Around 4.8 million and 7.89 million deaths occurred worldwide due to COVID-19 in 2020 and 2021, respectively. Age-standardized rates varied highly among GBD super-regions, with the highest in sub-Saharan Africa and the lowest in Southeast and East Asia and Oceania. OPRM and COVID-19 deaths also varied substantially by age, with older age groups being disproportionately affected.
In 1990, the three leading causes of YLLs globally were CMNN diseases. Further, neonatal disorders remained the leading cause in 2019, but NCDs, viz., ischemic heart disease and stroke, replaced the second and third leading causes, respectively. However, COVID-19 was the second leading cause of YLLs in 2021, with neonatal disorders and ischemic heart disease ranking first and third, respectively.
There have been long-standing positive trends in global life expectancy since the 1990s. Overall, life expectancy increased by 7.8 years between 1990 and 2019. However, during 2019-21, it decreased by 2.2 years due to COVID-19 and OPRM. Despite this decline, there was an overall increase of 6.2 years throughout the study period.
The decrease in mortality from enteric infections (paratyphoid, typhoid, and diarrheal diseases) affected the increase in global life expectancy. The reduction in deaths due to lower respiratory infection had the second most significant impact. All seven super-regions had an increase in life expectancy from 1990 to 2021.
Southeast and East Asia and Oceania had the highest gain (8.3 years), mainly due to lower mortality from chronic respiratory diseases. South Asia had the second largest gain (7.8 years) in life expectancy, mainly due to decreased mortality from enteric infections. Notably, Latin America and the Caribbean superregion had the largest decline in life expectancy (3.6 years) due to COVID-19.
The decline in mortality due to enteric disease substantially impacted global life expectancy. Mortality concentration emerged as 160 countries/territories made progress in CMNN disease mortality. Deaths were more concentrated in some regions or countries. For instance, 90% of deaths due to enteric infections in areas with 63% of the population of children under five years in 1990 reduced to areas with 51% of the population in 2021.
Further, the reduction in lower respiratory infections positively affected life expectancy in regions such as eastern and western sub-Saharan Africa and Andean Latin America. Moreover, reductions in stroke increased life expectancy by 0.8 years. However, stroke deaths were not concentrated. Overall, NCDs did not show a mortality concentration at large.

Conclusions​

In sum, the present analysis offered insights into the global disease landscape before and during the two years of the COVID-19 pandemic. The findings showed that, after three decades of life expectancy improvements and reductions in age-standardized mortality rates, COVID-19 disrupted trends in the epidemiological transition, reversing long-standing progress.
COVID-19 was the second leading age-standardized cause of death in 2021, profoundly impacting global life expectancy. It decreased life expectancy approximately as much as reductions in communicable diseases and NCDs have improved over decades. The study suggests that improved life expectancy outcomes could be achieved by leveraging past successes in mortality reduction.
 

Midland hospital puts visitor restrictions in place after COVID-19 outbreak​

Universal masking and eye protection are required in unit.

ByMetroland StaffMidland Mirror
Monday, April 8, 2024
1 min to read
Article was updated 2 mins ago

Georgian Bay General Hospital

Georgian Bay General Hospital.
Metroland file photo



Georgian Bay General Hospital in Midland has put visitor restrictions in place after 11 patients in one of the hospital’s unit contracted COVID-19
The hospital, in collaboration with the Simcoe Muskoka District Health Unit, declared a COVID-19 outbreak in the 1 North Complex Continuing Care Unit on April 8.
The hospital has put in place enhanced cleaning and other infection prevention and control measures, as well as increasing testing of patients and staff.
Visitation to the unit is limited to essential caregivers only and the unit is closed to admissions at this time. Universal masking and eye protection is required for anyone entering a unit experiencing an outbreak.
 

$1K Covid Drug Paxlovid DOES NOTHING?! Report​


 

“Pfizer LIED About Covid-19 Jabs” | Watchdog Accuses Pfizer Of Promoting 'Unlicensed Vaccine'​


 

B.C. launches spring COVID-19 booster program, targeting vulnerable and unvaccinated​

VICTORIA — British Columbia is rolling out another round of COVID-19 vaccination boosters, with invitations starting to go out Monday. Ministry of Health says people who haven't received a booster against the XBB. 1.
Canadian Pressabout an hour ago22 minutes ago





20240408180416-66146ceac0770d953725f374jpeg
A person draws out Moderna vaccine during a drive through COVID-19 vaccine clinic in Kingston, Ont., on Sunday Jan. 2, 2022. British Columbia is rolling out another round of COVID-19 vaccination boosters, with invitations starting to go out Monday. THE CANADIAN PRESS/Lars Hagberg
VICTORIA — British Columbia is rolling out another round of COVID-19 vaccination boosters, with invitations starting to go out Monday.
Ministry of Health says people who haven't received a booster against the XBB. 1.5 Omicron variant of COVID-19 will be among those offered the free shot.
Others who will be invited include adults aged 65 and older, Indigenous adults 55 and over, residents of long-term care homes and assisted-living facilities, and anyone older than six months who is "clinically extremely vulnerable."
The ministry says in a statement that although the spring program is focused on those most at risk or those who haven't received an updated vaccine, anyone who wants a booster can book an appointment or walk into a pharmacy where the shots are available.
It says about 3.9 million people in B.C. have yet to receive the XBB. 1.5 vaccine.
The vaccines will be offered at pharmacies, regional health authority clinics, primary care offices and community health centres.

The statement says the peak of the respiratory illness season has passed, but COVID-19 continues to spread at lower levels in the community.
It says protection provided by COVID-19 vaccines decreases over time, particularly for older people, and a spring booster will ensure protection.
The ministry says the 2023-24 respiratory illness immunization campaign for the general population, launched on Oct. 10, saw almost 1.5 million shots of COVID-19 vaccine administered and 1.56 million doses of influenza vaccines.
This report by The Canadian Press was first published April. 8, 2024.
The Canadian Press
 


Respiratory Virus Data​

The respiratory virus data tool consists of surveillance dashboards and summary reports.

Respiratory virus data are updated weekly on Thursdays.

April 4, 2024 Summary:

Epi week 13: Mar 24 to Mar 30, 2024​

Respiratory virus activity overall continues to decrease, following a peak in late December.​

  • Influenza B has remained elevated in wastewater, but overall activity is low.

  • Influenza A activity indicators have decreased or remained stable. Among subtyped influenza A samples over the past four weeks, both H1 and H3 are circulating.

  • RSV activity indicators have decreased or remained stable.

  • COVID-19 activity has decreased or remained stable across indicators, including decreased COVID-19 hospitalizations since early March.

  • The proportions of primary care and emergency department visits for respiratory symptoms have remained stable.

National and international context​

Influenza​

  • In Canada, most influenza activity indicators have decreased and are within or below expected levels typical of this time of year.

  • In the USA, influenza activity remains elevated nationally, but percent positivity has continued to decrease.

RSV and other viruses​

  • In Canada, RSV percent positivity has decreased over recent weeks. All other non-SARS-CoV-2 respiratory viruses were within expected levels typical for this time of year.

COVID-19​

  • In Canada, COVID-19 activity has continued to slowly decrease or remains at low levels.

  • In the USA, COVID-19 activity has continued to decrease.
 

COVID outbreak closes Palmerston hospital to visitors​

This does not include essential care partners
Isabel Buckmaster, Local Journalism Initiative Reporterabout 4 hours ago





palmerstonhospital
Palmerston and District Hospital.Keegan Kozolanka/EloraFergusToday
Listen to this article
00:00:57

PALMERSTON – A COVID outbreak has been declared at the Palmerston and District Hospital.
According to a statement on the North Wellington Healthcare Alliance website, the Palmerston and District Hospital (PDH) has been experiencing an outbreak of COVID-19 since April 8.

As a result, no inpatient visiting is permitted for anyone except essential care partners.
Masks are also now required at the hospital and staff are asking people to practice physical distancing.
PDH remains open for admissions, the emergency department, diagnostic imaging, ambulatory care and day surgery.
Carressant Care in Harriston has been experiencing a facility-wide COVID-19 outbreak since April 4.
Isabel Buckmaster is the Local Journalism Initiative reporter for GuelphToday. LJI is a federally-funded program.
 

Long COVID leaves distinctive signs in blood which could be targets for treatment, study suggests​

Findings from the largest UK study of patients admitted to hospital with coronavirus show long COVID leads to ongoing inflammation which can be detected in the blood.
Monday 8 April 2024 23:18, UK

Pic: iStock

Image:File pic: iStock
Why you can trust Sky News
Long COVID leaves distinctive signs in the blood which could potentially be targeted for treatment, research suggests.
Findings from the largest UK study of patients admitted to hospital with coronavirus show long COVID leads to ongoing inflammation which can be detected in the blood.
Sponsored link
















Why young men and women are drifting apartWhy young men and women are drifting apartThe Economist


Neuropathy is not from Low vitamin B. Meet the Real Enemy of Neuropathy (Stop Doing This)Neuropathy is not from Low vitamin B. Meet the Real Enemy of Neuropathy (Stop Doing This)neuropathy.pro


'Never Paying for Prime'—Why 20,000 Users Prefer This Shopping Secret'Never Paying for Prime'—Why 20,000 Users Prefer This Shopping SecretThis simple trick can save tons of money on Amazon, but most prime members are ignoring itonlineshoppingtools.com



The analysis of more than 650 people who had been in hospital with severe COVID-19 found patients with prolonged symptoms showed evidence of their immune system being activated.
How the activation happened depended on the type of symptoms they mainly had, for example fatigue or brain fog.
The research, led by Imperial College London, suggests existing drugs which modulate the body's immune system could be helpful in treating long COVID and should be investigated in future research.


Professor Peter Openshaw, from Imperial's National Heart and Lung Institute, said: "With one in 10 Sars-CoV-2 infections leading to long COVID and an estimated 65 million people around the world suffering from ongoing symptoms, we urgently need more research to understand this condition."
He said the study "is an important step forward and provides crucial insights into what causes long COVID".

MORE ON COVID-19​

Related Topics:​

He added: "I do think that there is a hopeful message which says that there are these biological pathways that are activated from different forms of persistent symptomatology after COVID, and people aren't imagining it.
"It's something which is genuinely happening to them."


Advertisement

Click to subscribe to the Sky News Daily wherever you get your podcasts
The study, published in the journal Nature Immunology, compared 426 people who were experiencing symptoms with long COVID - having been admitted to hospital with COVID-19 at least six months prior to the study - with 233 people who were admitted to hospital for COVID-19 but who had fully recovered.
Samples of blood plasma were taken and levels of proteins known to be involved in inflammation and immune system modulation were measured.
Researchers found that compared to patients who had fully recovered, those with long COVID showed a pattern of immune system activation indicating inflammation of myeloid cells - which are formed in bone marrow and produce white blood cells, which respond to damage and infection - and activation of a family of immune system proteins called the complement system.
Follow Sky News on WhatsApp
Follow Sky News on WhatsApp
Keep up with all the latest news from the UK and around the world by following Sky News

Dr Felicity Liew, from Imperial's National Heart and Lung Institute, said: "Our findings indicate that complement activation and myeloid inflammation could be a common feature of long COVID after hospitalisation, regardless of symptom type.
"It is unusual to find evidence of ongoing complement activation several months after acute infection has resolved, suggesting that long COVID symptoms are a result of active inflammation.
"However, we can't be sure that this is applicable to all types of long COVID, especially if symptoms occur after non-hospitalised infection."
 

Nirmatrelvir fails to shorten COVID-19 symptoms in latest trial​

NewsGuard 100/100 Score
Hugo Francisco de Souza
By Hugo Francisco de SouzaApr 8 2024Reviewed by Benedette Cuffari, M.Sc.
In a recent study published in The New England Journal of Medicine, researchers evaluate the efficacy of nirmatrelvir in combination with ritonavir against the coronavirus disease 2019 (COVID-19).
ImageForNews_776655_1712627001072746.jpg
Study: Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19. Image Credit: Alexsey t17 / Shutterstock.com

A brief history of COVID-19 patient care​

Since its emergence at the end of 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, has infected almost 700 million individuals and claimed over seven million lives worldwide. COVID-19 is associated with a wide range of pathologies in different populations, with the very young and elderly at the most significant risk of mortality and morbidity.
Rapid global medical research and vaccination programs have significantly reduced the burden of COVID-19 by attenuating SARS-CoV-2 transmission. Currently, COVID-19 patients are treated symptomatically through general antiviral interventions; however, an extensive search for a COVID-19-specific cure is still in the clinical trials phase.
Nirmatrelvir is an orally administered antiviral agent that inhibits the SARS-CoV-2 main protease (Mpro), which is critical for viral replication. Nirmatrelvir is administered with the pharmacokinetic enhancer ritonavir to inhibit metabolism by CYP3A4."
One of the most promising antiviral therapies currently in clinical trials is the combination of nirmatrelvir and ritonavir. In unvaccinated adults, phase II and III clinical trials have produced promising results by reducing COVID-19 mortality risk by over 80%. Nevertheless, the anti-COVID-19 benefits of this intervention in vaccinated individuals remain unverified.

About the study​

In the current study, researchers evaluate the efficacy and side effects of nirmatrelvir-ritonavir in non-hospitalized patients of various ages, ethnicities, and infection severity.
Data were obtained from the Evaluation of Protease Inhibition for Covid-19 in Standard-Risk Patients (EPIC-SR) trial, which is a randomized, double-blind, and placebo-controlled trial involving adult participants 18 years of age and older with laboratory reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed COVID-19. Individuals were enrolled in the study between August 2021 and July 2022 if their symptoms initially appeared in the five days prior to study enrollment.
Study participants were randomly assigned to receive either the nirmatrelvir-ritonavir intervention, which comprised 300 mg of nirmatrelvir and 100 mg of ritonavir, or placebo. The dosage was fixed once every 12 hours for five days, thus leading to a final total of 10 doses.
For statistical analyses, randomization was stratified across vaccination status, geographic region, and COVID-19 symptom onset. Data collection included participants' sociodemographic, anthropometric, and medical records.
Digital diaries were also used to record daily intervention use, COVID-19 symptom severity on a four-point scale, and associated side effects. Efficacy measurements were conducted through day 34.
Sustained alleviation was considered to have occurred on the first of four consecutive days during which all symptoms that had been scored as moderate or severe and as mild or absent at baseline were scored as mild or absent and as absent, respectively."

Study findings and relevance​

Of the 1,296 participants initially enrolled in the study, 1,288 individuals, 654 of whom received nirmatrelvir-ritonavir and 634 placebo, provided completed data and were included in the statistical analyses. The study cohort primarily comprised women and individuals of the White ethnicity at 54% and 78.5%, respectively.
Genetics & Genomics - Second Edition eBook NEW EDITION NOW OUT - Compilation of the top interviews, articles, and news in the last year.Download the latest edition
About 57% of the study cohort were vaccinated, with smoking as the most commonly severe COVID-19 risk factor reported among 13.3% of the study participants. Study intervention compliance was high across both cohorts at 94.8% and 96.5% for nirmatrelvir-ritonavir and placebo, respectively.
Efficacy evaluations revealed no statistically different outcomes between nirmatrelvir-ritonavir and placebo treatment cohorts. While the safety evaluation found no statistically significant differences between the side effects reported across trial groups, dysgeusia, diarrhea, and nausea were often reported by those who received nirmatrelvir-ritonavir during the study.

Conclusions​

The study findings suggest that nirmatrelvir-ritonavir may not be as effective as suspected in alleviating adverse viral SARS-CoV-2 outcomes, especially in symptomatic, non-hospitalized, vaccinated, or unvaccinated adults. Given the known and study-reported side effects, nirmatrelvir-ritonavir cannot yet be established as a safe and beneficial treatment for severe COVID-19 outpatients, irrespective of prior vaccination status.
Nirmatrelvir–ritonavir was not associated with a significantly shorter time to sustained alleviation of COVID-19 symptoms than placebo, and the usefulness of nirmatrelvir–ritonavir in patients who are not at high risk for severe COVID-19 has not been established."
 

B.C.’s vulnerable urged to get COVID-19 booster as peak of illness season passes​

Amy_Judd_Web1.jpg

By Amy Judd Global News
Posted April 8, 2024 6:20 pm
Updated April 8, 2024 9:50 pm
1 min read


Video will begin after these messages...
close video
Starting Monday, new COVID-19 boosters are launching in B.C. as the annual respiratory illness season comes to an end.
LEAVE A COMMENTSHARE THIS ITEM ON FACEBOOKSHARE THIS ITEM ON TWITTERSEND THIS PAGE TO SOMEONE VIA EMAILSEE MORE SHARING OPTIONS

DESCREASE ARTICLE FONT SIZE
INCREASE ARTICLE FONT SIZE
B.C. is launching a spring COVID-19 booster campaign.
70c8fc80

Starting Monday, April 8, people who are at higher risk of infections are being urged to roll up their sleeves and get a booster.
It will be available throughout the province at pharmacies, regional health-authority clinics, some primary-care offices, and community health centres.
Health Minister Adrian Dix said the peak of respiratory illness season has passed but the SARS CoV-2 virus continues to circulate at lower levels in the community.
People are still encouraged to wear masks in health-care settings but the additional infection prevention and control measures implemented in fall 2023 are no longer required at all times.
Click to play video: 'Report calls for more research and support for long COVID patients'


2:00Report calls for more research and support for long COVID patients
B.C. health officials recommend the following people consider receiving an additional dose of the XBB.1.5 COVID-19 vaccine:
STORY CONTINUES BELOW ADVERTISEMENT

  • Adults 65 and older;
  • Indigenous adults 55 and older;
  • Adult residents of long-term care homes and assisted-living facilities (including those awaiting placement); and
  • Individuals six months and older who have been diagnosed as clinically extremely vulnerable (a CEV 1 or CEV 2 condition).
The latest health and medical news emailed to you every Sunday.
In addition, anyone who feels like they would benefit from an additional dose of the XBB.1.5 COVID-19 vaccine can contact the call centre at 1-833-838-2323 to book an appointment or walk in to a pharmacy where the vaccine is available.
As of end of day on March 31, 2024, B.C. had administered 1,457,246 doses of COVID-19 vaccines and 1,562,023 doses of influenza vaccines.
 

2 more COVID deaths in N.B., no new flu deaths​

Respiratory diseases remain stable, report says​

sam-farley.jpg

Sam Farley · CBC News · Posted: Apr 09, 2024 2:49 PM EDT | Last Updated: 5 hours ago
A paramedic wearing a baseball hat and medical mask walks beside an ambulance parked outside a hospital.

In the latest week of data, there were two more COVID deaths in New Brunswick and no influenza deaths. (CBC)

Social Sharing​

  • Facebook
  • X
  • Email
  • Reddit
  • LinkedIn

comments
Two more New Brunswickers have died from COVID-19 during the time period of March 24 through March 30, according to the latest figures from the province.
Both deaths were in the age 65 and above group.
COVID levels remained moderate, the report said, with most indicators of the disease decreasing. The week before, there were three COVID deaths.
There were 36 confirmed COVID cases and 13 hospitalizations during the reporting period, 12 of which were people aged 65 and up. One hospitalization was in the age range of 20 to 44. None of the COVID hospitalizations were in the ICU.
There were two lab-confirmed COVID outbreaks "in other facilities." This means the outbreaks were not in nursing homes.
The positivity rate — or the percentage of lab tests performed that produced a positive result — for COVID tests was four per cent, which is down from the previous report.
The number of COVID cases, outbreaks, hospital admissions and percent positivity are all down from the previous reporting period.
The total of New Brunswick deaths from COVID is now 1,027, but the real total is unknown because the Department of Health only counts deaths in hospitals.
This respiratory season has now seen 91 COVID deaths in hospitals.

No flu deaths​

There were no new flu deaths, and "influenza activity remained relatively stable" for the time period, the report said.
This respiratory season has seen 26 Influenza deaths in hospitals.
There were 115 flu cases for the week reported, with three hospitalizations, none of which were in the ICU. This is a decrease in hospitalizations from last week.
Two of the hospitalizations were in the 65 and above age group, with the third being between 45 and 64.
That brings the total number of flu cases this season in the province to 3,249.
With two flu outbreaks, that number is up from last week's numbers. They were both in nursing homes, the report says.
The number of cases, percent positivity and deaths are all stable from last week.
Since Oct. 4, there have been 149,077 COVID vaccinations administered and 222,855 Influenza vaccinations.
 

PMID38567363PMC10984316
Apr 3, 2024
SARS-CoV-2 seroprevalence in Nova Scotia blood donors.
O'Brien, Sheila F; Deeks, Shelley L; Hatchette, Todd; Pambrun, Chantale; Drews, Steven J

J Assoc Med Microbiol Infect Dis Can
Full Text
Diagnosis
BACKGROUND: SARS-CoV-2 seroprevalence monitors cumulative infection rates irrespective of case testing protocols. We aimed to describe Nova Scotia blood donor seroprevalence in relation to public health policy and reported data over the course of the COVID-19 pandemic (May 2020 to August 2022). METHODS: Monthly random Nova Scotia blood donation samples (24,258 in total) were tested for SARS-CoV-2 infection antibodies (anti-nucleocapsid) from May 2020 to August 2022, and vaccination antibodies (anti-spike) from January 2021 to August 2022. Multivariable logistic regression for infection antibodies and vaccination antibodies separately with month, age, sex, and racialization identified independent predictors. The provincial nucleic acid amplification test (NAAT)-positive case rate over the pandemic was calculated from publicly available data. RESULTS: Anti-N seroprevalence was 3.8% in January 2022, increasing to 50.8% in August 2022. The general population COVID-19 case rate was 3.5% in January 2022, increasing to 12.5% in August 2022. The percentage of NAAT-positive samples in public health laboratories increased from 1% in November 2021 to a peak of 30.7% in April 2022 with decreasing numbers of tests performed. Higher proportions of younger donors as well as Black, Indigenous, and racialized blood donors were more likely to have infection antibodies (p < 0.01). Vaccination antibodies increased to 100% over 2021, initially in older donors (60+ years), and followed by progressively younger age groups. CONCLUSIONS: SARS-CoV-2 infection rates were relatively low in Nova Scotia until the more contagious Omicron variant dominated, after which about half of Nova Scotia donors had been infected despite most adults being vaccinated (although severity was much lower in vaccinated individuals). Most COVID-19 cases were detected by NAAT until Omicron arrived. When NAAT testing priorities focused on high-risk individuals, infection rates were better reflected by seroprevalence.
 

12-year-old describes 4-year battle with long COVID​

Theo Huot de Saint-Albin was just 9 when he first contracted COVID in 2020.
ByKatie Kindelan
April 10, 2024, 4:46 AM




theo-3-main-ht-jt-240403_1712188611883_hpMain_1x1.jpg


2:49

12-year-old boy describes 4-year battle with ‘invisible’ disease of long COVID
12-year-old boy describes 4-year battle with ‘invisible’ disease of long COVID
Theo Huot de Saint-Albin was just...Show More

Theo Huot de Saint-Albin was a 9-year-old elementary school student when he first contracted COVID-19 in July 2020, near the start of the coronavirus pandemic.
Four years later, as much of the world has moved on from the pandemic and resumed normal life, Theo, now nearly a teenager, is still battling the effects of long COVID.
"What happened directly after COVID-19 was worse than my actual COVID-19," Theo, now in seventh grade, told "Good Morning America." For me, I have chronic migraines ... it doesn't mean the migraine is terrible every day. It's very unpredictable. It goes in waves. But it's always there. It never leaves."
Over the past four years, Theo has contracted COVID-19 a total of three times, and each case has been mild. It's what happens in the weeks and months after the COVID-19 diagnosis that he says has impacted his ability to learn, go to school and play with friends.
In addition to battling chronic migraines, Theo was also diagnosed with postural orthostatic tachycardia syndrome, or POTS, a blood circulation disorder that can cause dizziness, lightheadedness and a rapid heartbeat, according to the U.S. National Institute of Neurological Disorders and Stroke.
PHOTO: Theo Huot de Saint-Albin, now 12, first contracted COVID-19 in July 2020.

Theo Huot de Saint-Albin, now 12, first contracted COVID-19 in July 2020.
Meredith Eubanks
He said he also suffers from symptoms like muscle pain, extreme fatigue and brain fog, and takes around two dozen medications and supplements each day to help manage his symptoms.
"There's no real way to tell how I'm going to feel," Theo said, noting that some days he is able to go to school for only a half-day, while other days he feels closer to his pre-COVID-19 self, and still others he can't move beyond the couch all day.
"It's especially hard because it's 'invisible,'" Theo said of his long COVID diagnosis. "Sometimes it's hard to get people to believe you as well because they can empathize with something they know is there. 'Oh, you have a broken leg, I can see that. Wow, you can't walk. That must be tough.' But, your head hurts? 'I don't see a big bulge on your head. I don't see bandages wrapped around it.'"

An 'invisible' condition impacting potentially millions of kids​

While battling long COVID can seem lonely, Theo is far from alone, data shows.
An analysis published in February in the journal Pediatrics reported that as many as 5.8 million children in the United States have developed long COVID, or between 10% to 20% of children who have contracted COVID-19.

Figures from the Centers for Disease Control and Prevention show a smaller but still noteworthy estimate of 1.3% of children in the U.S. having had long COVID as of 2022.
Long COVID is diagnosed when patients still have symptoms at least four weeks after they have cleared the infection, according to the CDC. In some cases, like Theo's, symptoms can be present for months or years.
It's not clear if long COVID symptoms last a lifetime. Many people eventually recover, but scientists are still working to understand who is most affected, and why.

MORE: 4 years later, experts are just beginning to 'scratch the surface' of understanding long COVID​




Symptoms vary and can include fatigue, difficulty breathing, headaches, dizziness brain fog, joint and muscle pain and continued loss of taste and smell, according to the CDC.
In kids, symptoms of long COVID can also include rashes, diarrhea, heart issues and diabetes, according to the research published in Pediatrics.
Part of the complication with long COVID is there is no single test or bloodwork to diagnose it. Instead, doctors have to rule out other conditions and rely on patients to describe and track their symptoms, which can be difficult with kids.
For Theo, it took nearly two years for him to be diagnosed with long COVID, according to his mom Meredith Eubanks.
Eubanks said she was told "no" by doctors when she would ask if her son might have long COVID, and faced misdiagnoses along the way, like Lyme disease. Both she and Theo struggled to answer when asked roughly how many doctors he had seen over the past four years.
In April 2022, Eubanks said Theo was diagnosed with long COVID by an infectious disease group at a local children's hospital in Atlanta, where the family lives. But the hospital, according to Eubanks, had no answer to her question of "Now what?" in terms of treatments and rehabilitation.
PHOTO: Theo Huot de Saint-Albin, now 12, is pictured with his mom, Meredith Eubanks.

Theo Huot de Saint-Albin, now 12, is pictured with his mom, Meredith Eubanks.
Meredith Eubanks
For that, the family traveled over 600 miles to Baltimore, where Dr. Laura Malone, a pediatric neurologist, had established the Pediatric Post-COVID-19 Rehabilitation Clinic at the Kennedy Krieger Institute, a pediatric-focused nonprofit health organization affiliated with Johns Hopkins Medicine.
Theo Huot de Saint-Albin, now 12, is pictured on his first visit to the Pediatric Post-COVI...Show more
Meredith Eubanks
"They were the first place we got to where they were like, 'Here's a list of symptoms, and did you have any pre-COVID, and what did you have post-COVID?'" Eubanks said, recalling how Theo checked nearly all of the symptoms on the list. "I just remember that was such relief. It was just like, 'Oh, you know, they're recognizing this and it's official, and Theo is not alone.'"

Malone said she and her team at the Kennedy Krieger Institute established the clinic in the summer of 2020 as they saw reports of adults developing long COVID. As the pandemic continued, demand began to grow.
"Everybody was, early in the pandemic, very focused on hospitalized cases, and the sequela after people get care in the ICU or are very critically ill with the acute infection, and that's not generally what we see in pediatrics," Malone said. "Most children can have a relatively mild infection and then go on to develop long-term sequela. So, that took a little bit of time to recognize and for patients to seek care, both from their primary care doctors and then also from clinics like us."
Dr. Laura Malone, a pediatric neurologist, is director of the Pediatric Post-COVID-19 Reh...Show more
Kennedy Krieger Institute
As long COVID became more recognized, Malone said the clinic has seen steady demand from pediatric patients across the country, while she said other patients may go undiagnosed.
"You have to look at a lot of behavioral changes, especially in younger children, to say, 'Something seems off'.' So I do think that [long COVID] is probably a little bit under-recognized still," Malone said. "We do see that there can be a lot of resiliency in children, and so despite them sometimes maybe having the symptoms, they may not always bring it up to family members or doctors but rather just try and manage the symptoms, and it's only when it gets to be intolerable that sometimes it will present to more medical care."

Helping kids return to 'normal' life​

Along with there being no diagnostic test for long COVID, there is also no cure for the condition. Much of what can be done for patients is symptom management, according to Malone.
For kids, she said that means helping them manage their symptoms so they can, at least to some degree, return to school and social activities.
"Participation in life and all the activities, including education, that kids are designed to be participating in is really important," Malone said. "One of our big focuses is to try to provide accommodations to get kids back into school, but meet them where they are, because they may not be able to do a full course load, or they may not be able to make it through the full day of school, but there is still benefit if they can go for an hour, and gradually increase that over time to getting them back into that sort of routine, and getting them back into the social aspects of school and the educational aspects."
PHOTO: Theo Huot de Saint-Albin, now 12, does water therapy as part of his recovery from long COVID.

Theo Huot de Saint-Albin, now 12, does water therapy as part of his recovery from long COVID.
Meredith Eubanks
Patients at the clinic see not only medical doctors like Malone, but a team of experts including behavioral and neuropsychologists, social workers, pain specialists and physical therapists.
Ellen Henning, Ph.D., a pediatric psychologist at the Kennedy Krieger Institute, said patients often struggle with anxiety and depression due to long COVID. She said new research is also suggesting that long COVID itself could be influencing mental health symptoms due to factors like inflammation in the brain and lower levels of serotonin.
"We learn new things constantly and we adjust as we as we go," Henning said. "We try to provide the best supports that we can and then we all are always integrating new knowledge and adjusting things as we need to."

MORE: New long COVID study uncovers high inflammation in patients as Senate calls for more research on 'crisis'​




In October, the clinic received a $5 million grant from the Department of Health and Human Services that it is using to help train school nurses and other community health care providers to identify long COVID in students and provide accommodations for students already diagnosed with the condition.
"We have a lot of families and children that say that they have to educate, sometimes, their providers and tell their doctors at home about what's going on and about long COVID," Malone said. "That can just be really exhausting for kid, so that's a big thing that we've been working on, and we're really proud of that."
Theo said while his long COVID symptoms continue, he has felt more at ease since receiving his diagnosis and as the condition becomes more recognized.
Theo Huot de Saint-Albin, now 12, was diagnosed with long COVID in 2022.
Meredith Eubanks
With the help of Malone and the team at the Kennedy Krieger Institute, Theo is back in school for periods of time and working on catching up with his classmates.
"We have a lot of hope," he said. "I know I'm going to finish school at some point. Maybe a little later than most people, but who knows. And I think I'm going to get better. With all the research that's going to come out, hopefully, something will help me more than anything else."



 

Users who are viewing this thread

Latest Posts

Back
Top